Side-by-side comparison of AI visibility scores, market position, and capabilities
Atlanta financial market infrastructure (NYSE: ICE) ~$9.3B FY2024 revenue; NYSE, ICE Brent/HH futures, Black Knight $11.7B mortgage tech acquisition 2023, Encompass LOS competing with CME and Tradeweb.
Intercontinental Exchange, Inc. (ICE) is an Atlanta, Georgia-based financial market infrastructure company — publicly traded on the New York Stock Exchange (NYSE: ICE) as an S&P 500 Financials component — operating exchanges and clearing houses for futures, options, and equity trading (ICE Futures US, ICE Futures Europe, New York Stock Exchange), providing fixed income data and analytics, and operating mortgage technology platforms (ICE Mortgage Technology — formerly Ellie Mae, Black Knight) through approximately 14,000 employees globally. In fiscal year 2024, ICE reported revenues of approximately $9.3 billion and adjusted net income of approximately $3.5 billion, integrating Black Knight (acquired in September 2023 for $11.7 billion — the largest acquisition in ICE's history, adding mortgage origination software, mortgage data analytics, and MLS real estate data) alongside the existing ICE Mortgage Technology (Ellie Mae Encompass LOS — the most widely used loan origination system in the US mortgage industry). CEO Jeff Sprecher founded Intercontinental Exchange in 2000 to create an electronic alternative to the open-outcry trading floor for energy commodity futures — growing ICE from an over-the-counter energy platform into a global financial market infrastructure company through acquisitions of the New York Board of Trade (NYBOT), ICE Futures Europe, NYSE Euronext ($8.2B in 2013), and Interactive Data Corporation's bond pricing data. ICE's three business platforms — Exchanges (futures and equities trading, clearing — 48% of revenue), Fixed Income and Data Services (bond pricing, analytics, reference data, index services — 30%), and Mortgage Technology (loan origination, servicing, data — 22%) — provide diversified financial infrastructure revenues across market cycle conditions.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.